Navigation Links
Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014
Date:9/30/2014

NEW YORK, Sept. 30, 2014 /PRNewswire/ -- Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014', provides an overview of the Pacific Northwest Biotechnology, LLC's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Pacific Northwest Biotechnology, LLC's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Pacific Northwest Biotechnology, LLC including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Pacific Northwest Biotechnology, LLC's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Pacific Northwest Biotechnology, LLC's pipeline products

Reasons to buy

- Evaluate Pacific Northwest Biotechnology, LLC's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Pacific Northwest Biotechnology, LLC in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Pacific Northwest Biotechnology, LLC's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Pacific Northwest Biotechnology, LLC and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pacific Northwest Biotechnology, LLC
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Pacific Northwest Biotechnology, LLC and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Read the full report: http://www.reportlinker.com/p02387356-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com
__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001


'/>"/>

SOURCE Reportlinker
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
2. Pacific Meso Center Receives Generous Donation to First Free-Standing Mesothelioma Research Laboratory in Los Angeles
3. Codexis to Present at the Pacific Crest and Jefferies Conferences
4. Sigma-Aldrich Opens New Wuxi Packaging and Quality Control Facilities to Enhance Capabilities Serving China and Asia-Pacific Region
5. Cancer Immunotherapy Expert Joins Pacific Meso Center Research Team
6. Pacific BioStorage Announces an Exciting New First for The Life Sciences Industry in Southern California
7. BioStorage Technologies Continues Global Growth; Announces Strategic Expansion Into Asia Pacific and New General Manager APAC
8. The Law Office of Roger G. Worthington, P.C. - Longtime Supporter of the Pacific Meso Center - Donates $100,000 for Mesothelioma Research
9. Frost & Sullivan: Asia Pacific Infectious Disease Diagnostics Market Grows as Economies Boom and Countries Become Image Conscious
10. Human Genome Decoder and Artificial Life Creator, J. Craig Venter to Speak at "The Atlantic Meets the Pacific"
11. All Market Research New Report @ Polyvinyl Chloride (PVC) Global Market to 2020 - Growth from Asia-Pacific Construction, Packaging and Electrical Sectors Continues to Drive Demand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is ... $3950. With 50 million stem cells total, patients may choose which extremities they would ... for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is ...
(Date:7/31/2020)... ... July 29, 2020 , ... eSource has long been touted as ... cover the history of eSource, the reasons it did not take off as quickly ... site source, the industry is moving towards capturing data electronically for clinical trials and ...
(Date:7/18/2020)... ... ... “We are thrilled to deliver this new technology to the industry” said Matt Hundt, ... market and we were pleased that the IFT jury recognized that.” reFRESH™ couples the ... natural way to extend the shelf life and improve the safety of perishable foods ...
(Date:7/10/2020)... HONG KONG (PRWEB) , ... July 09, 2020 ... ... chemical compound called 1-phenyl-2-thiourea (PTU) is commonly used to suppress pigment formation in ... years, the PolyU research team led by Dr MA has been using the ...
Breaking Biology Technology:
(Date:7/18/2020)... ... July 17, 2020 , ... Commercial launch readiness is a critical stage in ... COVID cure or vaccine, the global economic downturn will only increase price pressures overall ... away and capturing full value from every product launch is critical. However, history shows ...
(Date:7/2/2020)... (PRWEB) , ... July 02, ... ... Biology Systems, B.V. (MBS) has announced a publication detailing the use of ... reverse transcription polymerase chain reaction (RT-PCR) in 16 minutes. The article, titled ...
(Date:6/25/2020)... Mass. (PRWEB) , ... June 24, 2020 , ... ... of cloud-based enterprise software and software-driven clinical data services that accelerate drug development, ... for low-dose selinexor, an XPO1 inhibitor, in hospitalized patients with severe COVID-19. This ...
Breaking Biology News(10 mins):